Why Sterile Manufacturing Matters More Than Ever Strategic Insights For ADC Development, Lyophilization, And CDMO Partnership Success

Sterile manufacturing has become a strategic differentiator in modern drug development, particularly as antibody-drug conjugates (ADCs) introduce new levels of complexity across formulation, fill/finish, and lyophilization.

This collection examines the critical decisions that can influence timelines, product quality, and regulatory success, from determining the right balance between in-house manufacturing and outsourcing to selecting CDMO partners with the expertise and infrastructure needed for sterile operations. It also explores the unique lyophilization challenges associated with ADCs, including process development, cycle optimization, and critical quality attributes. Technical perspectives on controlled ice nucleation, primary and secondary drying, and automated visual inspection provide practical insights into improving efficiency, consistency, and product integrity.

For sponsors navigating increasingly demanding development environments, these perspectives offer valuable guidance for reducing risk and accelerating progress toward commercialization.